# Caparaó Brazil (Coffea arabica)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/capara-brazil
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-30
**Evidence Score:** 2 / 10
**Category:** Coffee Cultivars
**Also Known As:** Caparaó coffee, Caparaó arabica, Caparaó region coffee, Minas Gerais-Espírito Santo arabica, Brazilian Caparaó cultivar

## Overview

Caparaó Brazil is a Coffea arabica cultivar grown in the Caparaó mountain region of Minas Gerais and Espírito Santo, Brazil, containing caffeine, chlorogenic acids, and diterpenes such as cafestol and kahweol as primary bioactive compounds. These compounds interact with adenosine receptors, [antioxidant](/ingredients/condition/antioxidant) pathways, and [glucose metabolism](/ingredients/condition/weight-management) enzymes, though no clinical trials have specifically studied this regional cultivar.

## Health Benefits

• No clinical evidence exists specifically for Caparaó Brazil cultivar health benefits
• General Coffea arabica consumption may reduce type 2 diabetes risk (evidence from non-region-specific meta-analyses)
• May potentially lower Parkinson's disease risk (based on general coffee studies, not Caparaó-specific)
• No biomedical studies have examined this specific cultivar variant
• Current evidence is limited to culinary/sensory qualities rather than health outcomes

## Mechanism of Action

Caffeine in Coffea arabica competitively antagonizes adenosine A1 and A2A receptors in the central nervous system, increasing [dopamine](/ingredients/condition/mood)rgic and noradrenergic neurotransmission, which underlies both cognitive stimulation and the proposed [neuroprotective](/ingredients/condition/cognitive) association with Parkinson's disease risk reduction. Chlorogenic acids, particularly 5-caffeoylquinic acid, inhibit glucose-6-phosphatase and slow intestinal glucose absorption, contributing to improved postprandial glycemic control and reduced type 2 diabetes risk observed in epidemiological studies. Diterpenes cafestol and kahweol activate the Nrf2/ARE [antioxidant](/ingredients/condition/antioxidant) pathway and modulate [phase II detox](/ingredients/condition/detox)ification enzymes, though these compounds are largely removed by paper filtration during brewing.

## Clinical Summary

No randomized controlled trials or observational studies have specifically examined the Caparaó Brazil cultivar; all health evidence is extrapolated from general Coffea arabica research. A 2014 meta-analysis published in Diabetes Care pooling 28 prospective cohort studies (n > 1,000,000) found that consuming 6 cups of coffee daily was associated with a 33% lower relative risk of type 2 diabetes compared to no consumption, with each additional cup linked to a roughly 6% incremental risk reduction. A 2002 meta-analysis in Annals of Neurology (n = 8 studies) reported that the highest coffee consumers had approximately a 31% lower risk of Parkinson's disease compared to non-consumers. Evidence quality for region-specific or cultivar-specific benefits is effectively absent, meaning outcomes for Caparaó Brazil in particular cannot be distinguished from those of any other arabica coffee.

## Nutritional Profile

**Macronutrients (per 100g green bean, approximate):** Protein: 10–13g; Lipids: 12–18g (predominantly linoleic acid ~40–45% and palmitic acid ~30–35% of total fatty acids); Total carbohydrates: 50–60g (including sucrose 6–9g, polysaccharides ~40–50g); Dietary fiber: 30–40g (largely galactomannans and arabinogalactans); Moisture: 10–12g. **Micronutrients:** Potassium: 1,500–1,800mg; Magnesium: 180–220mg; Phosphorus: 150–200mg; Calcium: 80–120mg; Iron: 3–5mg (low bioavailability due to chelation by chlorogenic acids and polyphenols); Zinc: 1–3mg; Manganese: 2–4mg; Niacin (vitamin B3): 15–25mg (largely bound as trigonelline, partially liberated during roasting); trace amounts of riboflavin (B2): ~0.2mg; thiamine (B1): ~0.1mg. **Key Bioactive Compounds:** Caffeine: 1.0–1.4g/100g green bean (typical Coffea arabica range; Caparaó lots from the Caparaó massif in Minas Gerais/Espírito Santo tend toward the mid-range ~1.1–1.3g due to higher altitude cultivation at 1,100–1,400m); Chlorogenic acids (CGAs): 5.5–8.0g/100g (predominantly 5-O-caffeoylquinic acid [5-CQA] at ~60% of total CGAs, with 3-CQA and 4-CQA as secondary isomers; feruloylquinic acids ~10–15% of total CGAs); Trigonelline: 0.8–1.2g/100g (converted partially to nicotinic acid/niacin upon roasting); Diterpenes: cafestol ~0.4–0.7g/100g and kahweol ~0.3–0.6g/100g (lipid fraction; bioavailability dependent on brewing method—unfiltered methods retain these, paper filtration removes >80%); Melanoidins (formed post-roast): 20–25% of roasted bean dry weight, contributing to antioxidant capacity and [prebiotic](/ingredients/condition/gut-health) function; Sucrose-derived caramelization products post-roast. **[Antioxidant Activity](/ingredients/condition/antioxidant):** ORAC values for brewed arabica coffee generally 15,000–25,000 µmol TE/L; CGAs are primary contributors but undergo ~50–70% degradation during medium-dark roasting, forming lactones with distinct bioactivity. **Bioavailability Notes:** CGAs are partially hydrolyzed in the small intestine by esterases, yielding caffeic acid and quinic acid; ~30% of ingested CGAs reach the colon intact where microbial [metabolism](/ingredients/condition/weight-management) produces dihydrocaffeic acid and ferulic acid derivatives with systemic bioavailability; caffeine is nearly 100% bioavailable with peak plasma concentration at ~30–60 minutes post-ingestion; diterpene bioavailability is highly brew-method dependent (espresso and French press retain significant amounts, drip-filtered coffee retains minimal); potassium and magnesium from coffee contribute meaningfully to daily intake (one 240mL cup provides ~100–150mg K and ~7–12mg Mg). **Caparaó-Specific Notes:** No peer-reviewed compositional analyses exist exclusively for beans marketed as 'Caparaó Brazil'; however, the high-altitude terroir (Serra do Caparaó, often >1,100m) typically promotes slower cherry maturation, which in arabica correlates with higher sucrose content, greater CGA concentration, and enhanced aromatic precursor density compared to lower-altitude Brazilian arabica. Cultivar varieties commonly grown in this region include Catuaí, Mundo Novo, and Bourbon derivatives, all within the standard Coffea arabica compositional range described above.

## Dosage & Preparation

No clinically studied dosage ranges exist for Caparaó Brazil in biomedical contexts. General Coffea arabica consumption in non-region-specific studies uses 3-5 cups/day (approximately 300-500 mg caffeine) from brewed powder, but no standardization exists for this specific cultivar. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Caffeine consumed in doses above 400 mg per day in healthy adults may cause [insomnia](/ingredients/condition/sleep), tachycardia, anxiety, and elevated [blood pressure](/ingredients/condition/heart-health), with sensitivity varying substantially by CYP1A2 genotype, which governs caffeine [metabolism](/ingredients/condition/weight-management) rate. Coffea arabica preparations can interact with stimulant medications, MAO inhibitors, and certain fluoroquinolone antibiotics such as ciprofloxacin, which inhibit CYP1A2 and can raise plasma caffeine levels two- to fourfold. Pregnant individuals are advised by most health agencies to limit caffeine intake to under 200 mg per day due to associations between high intake and increased miscarriage risk and low birth weight observed in cohort studies. Individuals with cardiac arrhythmias, severe hypertension, anxiety disorders, or gastroesophageal reflux disease should exercise caution, and those taking anticoagulants such as warfarin should monitor INR as chlorogenic acids may have modest antiplatelet effects.

## Scientific Research

No clinical trials, RCTs, or meta-analyses specific to Caparaó Brazil Coffea arabica were identified in available research. While general coffee consumption studies exist (PMIDs 30608007, 34927534), these do not distinguish regional cultivar variants and cannot be applied to Caparaó specifically.

## Historical & Cultural Context

Caparaó Coffea arabica has no documented historical use in traditional medicine systems, being primarily recognized since 2021 for its specialty coffee qualities. While Coffea arabica broadly has traditional uses in Ethiopian and Yemeni systems dating to the 15th century, Caparaó production has focused on commercial quality improvement since the early 2000s.

## Synergistic Combinations

No synergistic ingredients studied with Caparaó Brazil specifically

## Frequently Asked Questions

### Is Caparaó Brazil coffee different from regular arabica coffee in terms of health benefits?

No clinical evidence exists to distinguish Caparaó Brazil from other Coffea arabica coffees regarding health benefits; the cultivar designation refers to geographic origin and flavor profile, not a unique phytochemical composition. Chlorogenic acid, caffeine, and diterpene concentrations vary more with roast level, processing method, and brewing technique than with regional cultivar identity. All available health evidence for Caparaó Brazil is extrapolated from studies on generic arabica coffee.

### How much Caparaó Brazil coffee would you need to drink to potentially lower type 2 diabetes risk?

Meta-analyses on general coffee consumption suggest the association with reduced type 2 diabetes risk is dose-dependent, with the strongest effect observed at approximately 6 cups per day (roughly 600 mg caffeine), yielding around a 33% lower relative risk versus non-drinkers. However, these figures come from epidemiological data on mixed coffee types and populations, not from Caparaó Brazil specifically, so a precise cultivar-specific dose cannot be stated. Moderate consumption of 3–4 cups daily (~300–400 mg caffeine) still shows meaningful risk reduction in the same meta-analyses without exceeding widely recommended caffeine limits.

### Does Caparaó Brazil coffee protect against Parkinson's disease?

General coffee epidemiology suggests an inverse association between habitual coffee consumption and Parkinson's disease risk, with a 2002 meta-analysis estimating roughly 31% lower risk among the highest consumers, likely mediated by caffeine's antagonism of adenosine A2A receptors in the basal ganglia. This association has not been studied for Caparaó Brazil as a distinct cultivar, and causal relationships have not been established since all data come from observational studies subject to confounding. The neuroprotective signal is considered biologically plausible but not proven to the standard required for a medical claim.

### What are the main bioactive compounds in Caparaó Brazil Coffea arabica?

The primary bioactive compounds in Coffea arabica, including the Caparaó Brazil cultivar, are caffeine (a methylxanthine adenosine receptor antagonist), chlorogenic acids (particularly 5-caffeoylquinic acid, a potent antioxidant and glucose metabolism modulator), and diterpenes cafestol and kahweol (Nrf2 pathway activators with hepatoprotective and anti-inflammatory properties). Trigonelline, a pyridine alkaloid that degrades to nicotinic acid during roasting, is also present and has been investigated for modest hypoglycemic activity. The exact concentrations of these compounds in Caparaó Brazil specifically have not been published in peer-reviewed literature to our knowledge.

### Is Caparaó Brazil coffee safe during pregnancy?

Like all caffeinated coffees, Caparaó Brazil should be consumed with caution during pregnancy; major health bodies including the WHO and ACOG recommend limiting total caffeine intake to under 200 mg per day for pregnant individuals, equivalent to roughly one to two standard cups. Cohort studies have associated maternal caffeine intake above 200–300 mg per day with increased risk of miscarriage and reduced fetal birth weight, though causality remains debated due to confounding variables. Pregnant individuals should consult a healthcare provider, especially since decaffeination still leaves small residual caffeine amounts and green coffee extracts in supplement form may contain substantially higher caffeine concentrations than brewed coffee.

### How does Caparaó Brazil coffee compare to other arabica cultivars in terms of caffeine content?

Caparaó Brazil, like most arabica cultivars, typically contains 1.2–1.5% caffeine by weight, which is lower than robusta varieties but consistent with other premium arabicas. The specific caffeine content of Caparaó Brazil has not been isolated in published research, so comparisons rely on general arabica benchmarks. Regional growing conditions in Brazil may influence caffeine levels slightly, but cultivar differences within arabica are generally minimal.

### What is the research status on Caparaó Brazil coffee's antioxidant profile compared to other arabica origins?

No published clinical studies have specifically analyzed the antioxidant compounds in Caparaó Brazil coffee, so direct comparisons with other arabica origins are not available in the scientific literature. General arabica coffee research shows chlorogenic acid and polyphenols as primary antioxidants, but cultivar-specific data for Caparaó Brazil does not exist. Any claims about this cultivar's antioxidant superiority would be speculative without dedicated biomedical analysis.

### Who should consider drinking Caparaó Brazil coffee, and who should avoid it?

Adults without caffeine sensitivity, uncontrolled hypertension, or anxiety disorders may consume Caparaó Brazil coffee as part of a regular diet, as it carries typical arabica caffeine levels and general coffee safety profiles. Pregnant women, nursing mothers, children, and individuals taking certain medications (particularly MAOIs or specific stimulants) should consult healthcare providers before consumption. Those with acid reflux or GI sensitivity may experience irritation, as is common with all coffee varieties.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*